A meta-analysis of 5 clinical trials encompassing 53 patients with Ewing sarcoma treated with IGF-1R-targeted antibodies in combination with or without mTOR inhibitors reported a two-fold increase in progression-free survival with the two-combination compared to IGF-1R antibodies alone (PFS 1.6 vs 3.3 months, p = 0.042) [179, 184]. The gene discussed is IGF1R; the disease is Ewing sarcoma.